Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

University of York develops new medical tool that could help surgeons during complex procedures

Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.

15 Feb 2013

SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the first quarter-ended December 31, 2012.

15 Feb 2013

When a ‘nudge’ may be ethical for patient decision aids

There may be some scenarios in which patient decision aids should be designed to “nudge” patients toward a particular treatment option, according to a report by US researchers.

12 Feb 2013

FDA approves Cardiva Medical's VASCADE Vascular Closure System

Cardiva Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS).

6 Feb 2013

Dilaforette receives approval to initiate sevuparin Phase II malaria study in India

Dilaforette, a Karolinska Development portfolio company, today announces that the company has approval from the regulatory authority in India to start a Phase II study with sevuparin in patients with moderate to severe malaria.

30 Jan 2013

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

2 Jan 2013

Thromboprophylaxis does more harm than good in head and neck surgery

Patients undergoing oncologic head and neck surgery do not benefit from thromboprophylaxis, report researchers.

2 Jan 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

The low molecular weight heparin enoxaparin is associated with an increased risk for major bleeding in patients who have moderate renal impairment, say US scientists in findings that have prompted calls for updates to dosing recommendations.

14 Dec 2012

GigaScience announces publication of whole-genome sequencing and analysis of Wuzhishan Pig

The international open-access journal GigaScience announces the publication of the whole-genome sequencing and analysis of the Wuzhishan Pig, an extensively inbred, miniature pig, which can serve as an excellent model for human medical research.

16 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.

2 Nov 2012

Obesity does not affect VTE risk after knee surgery

Being morbidly obese does not increase the risk for developing venous thromboembolism after total knee arthroplasty surgery, report US researchers.

15 Oct 2012

Arthroplasty wound complications linked to oral anticoagulant use

Multicenter research suggests that recovery from hip or knee arthroplasty may be significantly affected by choice of pharmaceutical thromboprophylaxis.

21 Sep 2012

Early CATCH improves thrombocytopenia outcomes

One in five patients using heparin to protect against venous thromboembolism develops thrombocytopenia, reveal results from the CATCH Registry.

12 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Major decline in early mortality for STEMI patients: French registries

Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.

28 Aug 2012

GORE Hybrid Vascular Graft receives CE Mark approval

W. L. Gore & Associates (Gore) has received CE Mark for the GORE Hybrid Vascular Graft. The graft is designed to expand treatment options for optimal outflow by maximizing the number of access sites available.

20 Aug 2012